With a focus on patient safety at its core, AIM packs novel features for improved intra-op monitoring, safer outcomes, cost savings, and higher patient satisfaction. 

Risk Mitigation

  • Hypoxia is the number one cause of NORA injuries, AIM effectively delivers intra-tracheal FiO2 of 96%.
  • Accurate capnography provides early apnea alert, lowering the risk of impending hypoxia.
  • Easier airway resuscitation and seamless conversion to general anesthesia may further mitigate patient injuries. 
  • May lower the risk of airway fires leading to patient injuries and lawsuits

Cost Savings

  • General anesthesia is often defaulted for NORA patients even though the procedure may not require general anesthesia, adding $400-600 per case.
    • Medications – Zemuron $12/vial, Sugammadex $155/vial, Neostigmine $12/vial, Glycopyrolaye $52/vial
    • Supplies – GlideScope $15/blade, LMA $15, breathing circuit $8, suction catheter $4, temperature probe $4, bair-hugger, $20.
    • Longer wake-up time (average 8-12 minutes) leads to prolonged OR occupancy. The cost of OR time is $46.04/minute.
    • Longer recovery room stay (PONV, history of sleep apnea), costs undetermined.
  • Upon the discretion of the team providing patient care and the procedure’s nature, sedation may be considered with general anesthesia as a backup.

Improved Patient Satisfaction

  • Patients report higher satisfaction with sedation versus general anesthesia. 
  • Patient satisfaction scores are tied to Medicare reimbursement. Higher patient satisfaction also leads to patient loyalty, better clinical outcomes, patient compliance, and fewer malpractice suits. 
  • AIM eliminates bite blocks, facilitating easier placement of EGD and TEE scopes, lowering the risk for soft–palate injuries.
  • Without any straps around the neck, AIM may reduce anxiety in claustrophobic patients and those who don’t tolerate face mask placement.

Reduced Inventory of Multiple Alternative Devices

  • AIM’s compatibility across the broadest range of NORA cases and eliminating the need for bite-blocks could address hospitals’ logistical challenges while dealing with multiple vendors, stocking multiple devices, product availability, and price changes 

A third-party lab in CA recently tested AIM to collect data for FDA 510(k) submission. In a side-by-side comparison with the POM Mask, the sensor at the simulated patient’s trachea recorded 96% FiO2 with AIM and 58% FiO2 with the POM Mask.

Cost of operating room time references: